ClinicalTrials.gg
CompletedNCT07675161Updated Aug 25, 2026

MiniMed Fit Payload Wear Pediatric Study

An observational study in Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2) and Diabetes in Children, sponsored by Medtronic MiniMed, Inc.. Completed at 5 sites in United States. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Medtronic MiniMed, Inc. (part of Medtronic) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
59
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies in Diabetes Mellitus by Medtronic — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus · Medtronic.

Started
2026
with 3 others
Observational
6 of 35
none open now
Registered
35th of 35
by date

Among the 35 studies in Diabetes Mellitus by Medtronic, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 35th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

4 of the 35 studies in Diabetes Mellitus by Medtronic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Diabetes Mellitus by Medtronic, or all of them as a file.
02

Study summary

The purpose of this study is to assess MiniMed Fit Payload adhesive components in different wear locations over a 7-day period to support development of the future commercialized patch pump in participants 7-17 years of age.

03

Conditions studied

  • Diabetes (DM)
  • Diabetes (Insulin-requiring, Type 1 or Type 2)
  • Diabetes in Children
  • Diabetes in Adolescence

Browse trials for

04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Investigational Centers, example, primary care clinic, academic institution, etc.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with insulin-requiring diabetes
  • Participants 7-17 years of age
  • Participant and parent/guardian/legally authorized representative are able and willing to sign /assent

Exclusion criteria

Exclusion Criteria:

  • Participants who report known skin sensitivity or allergy to polycarbonate or pressure-sensitive adhesives, e.g., medical device adhesives, band-aids, other acrylic-containing adhesives.
  • Participants with any skin condition in the area where device placement (e.g., irritation, rash, infection) could occur, per participant report.
  • Participants who are pregnant (per self-report) at initial screening. If a participant becomes pregnant during the study, the site will follow procedures for study withdrawal.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
59 participants (actual)
Patient registry
No

Groups and cohorts

  • MiniMed Fit Payload adhesive components

    Pediatric participants with insulin-requiring diabetes using the MiniMed Fit Payload adhesive components in different wear locations over a 7-day period.

    Device: MiniMed Fit Payload adhesive components

Interventions

  • DeviceMiniMed Fit Payload adhesive components

    The MiniMed Fit Payload device used in this study will be made of polycarbonate materials, will not contain any electronic or mechanical components, and is intended to mimic the shape and weight of a future product. Each device will consist of the payload assembly and an adhesive patch, which will be adhered to the payload on one side and the subject's skin on the other.

06

What researchers measure

Primary outcomes

  1. Summary of device survival

    The number of MiniMed Fit Payload that remain securely attached to the skin at the end of day 7. This is a descriptive endpoint.

    Time frame: 7 Days

07

Study locations

5 sites
  • Sutter Institute for Medical Research
    Sacramento, California 95821-2123, United States
  • Sansum Diabetes Research Institute
    Santa Barbara, California 93105-4321, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Barry J Reiner MD LLC
    Baltimore, Maryland 21229, United States
  • Diabetes and Glandular Disease Clinic PA
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Aug 2026, 1 month.

Of 109 industry-sponsored observational studies under Diabetes Mellitus, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 39. This study's 1 month is below that.

Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 30, 2026
StartActual
Jun 25, 2026
Primary completionActual
Aug 7, 2026
CompletionActual
Aug 7, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07675161
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Jun 25, 2026
Primary completion
Aug 7, 2026
Completion
Aug 7, 2026
Last update
Aug 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion